The Standing Doctrine as Shield: What the Court's Abortion Pill Ruling Actually Decided

The Official Narrative

In June 2024, the Supreme Court issued a unanimous decision in FDA v. Alliance for Hippocratic Medicine, preserving access to mifepristone, the most commonly used abortion medication in the United States. The decision rejected a challenge brought by anti-abortion medical organizations seeking to reverse the FDA's 2016 and 2021 regulatory changes that expanded access to the drug. Justice Brett Kavanaugh, writing for the Court, ruled that the plaintiffs lacked Article III standing to bring the lawsuit.

Two justices—Samuel Alito and Clarence Thomas—filed separate statements. Neither dissented from the judgment itself, but both signaled they would have allowed the case to proceed differently or expressed concern about the standing analysis. The media narrative framed this as a "preservation" of abortion pill access over Alito and Thomas's objections, suggesting a substantive ideological split.

What Article III Standing Actually Requires

Article III of the Constitution limits federal judicial power to actual "Cases" and "Controversies." The Supreme Court has interpreted this to mean plaintiffs must demonstrate: (1) an injury in fact that is concrete and particularized; (2) a causal connection between the injury and the conduct complained of; and (3) a likelihood that the injury will be redressed by a favorable decision.

This is not a mere technicality. The standing doctrine serves as a structural gate, preventing federal courts from issuing advisory opinions or adjudicating generalized grievances. As the Court established in Lujan v. Defenders of Wildlife (1992), a plaintiff cannot manufacture standing by asserting a general interest in having others comply with the law. The injury must be personal and specific.

In FDA v. Alliance for Hippocratic Medicine, the plaintiffs—doctors and medical associations—argued they were injured because they might be forced to treat patients suffering complications from mifepristone. The Court found this theory too speculative. The doctors could not show they had ever been forced to treat such complications against their conscience, nor could they demonstrate a substantial likelihood this would occur in the future.

The Gap Between Narrative and Mechanism

The framing of this decision as "preserving abortion pill access" obscures what the Court actually did: it declined to hear the case at all. The unanimous judgment was procedural, not substantive. The Court did not rule that the FDA's actions were lawful, that mifepristone is safe, or that expanded access is constitutionally protected. It ruled only that these particular plaintiffs had no legal right to be in federal court making these arguments.

Justice Alito's statement did not dissent from this conclusion. Instead, he suggested that other plaintiffs—specifically, states—might have standing to bring similar challenges. He wrote separately to note that the Court's decision "does not vindicate the FDA's actions." Justice Thomas filed a concurrence arguing that the plaintiffs' associational standing theory was flawed, but he did not disagree with the outcome.

The gap here is significant. The public narrative implies a 7-2 ideological split on abortion pill access. The institutional reality is a 9-0 agreement that these plaintiffs failed to meet a constitutional threshold, with two justices signaling a roadmap for future litigation.

What the Omission Reveals

What is absent from the dominant framing is any discussion of why standing doctrine exists and what happens when it is bypassed. The Court has historically used standing as a check against the judiciary being weaponized for policy disputes better suited to the political branches. Allen v. Wright (1984) and Clapper v. Amnesty International (2013) both reinforced that federal courts do not exist to satisfy a plaintiff's general interest in having the executive branch follow the law.

By emphasizing Alito and Thomas's separate writings rather than the unanimous procedural ruling, the narrative invites the public to view this as a substantive endorsement of mifepristone access. It is not. The decision leaves the door open for state plaintiffs, as Alito noted, and for future regulatory challenges under different facts.

The omission is structurally significant because it misrepresents the durability of the outcome. Access to mifepristone remains subject to FDA regulation, congressional action, and potential future litigation by plaintiffs who can establish standing. The Court did not foreclose any of these pathways.

Competence, Intent, or Exploitation?

This is not a case of judicial incompetence. The standing analysis is consistent with decades of precedent. Nor is it necessarily a deliberate misrepresentation by the Court itself—the opinion is clear about its limits.

The gap lies in how the decision has been publicly framed. Whether by media simplification, advocacy group messaging, or political actors seeking to claim victory or sound alarms, the procedural dismissal has been converted into a substantive ruling. Alito and Thomas's separate writings—neither of which dissented from the judgment—have been recast as dissents on the merits.

This is exploitation of institutional ambiguity. The public does not generally distinguish between a case dismissed for lack of standing and a case decided on the merits. The Court's opinion does nothing to close that gap, and separate writings provide enough material for selective quotation.

What Structural Accountability Looks Like

The mechanism for correction here is transparency about what courts actually decide versus what advocates claim they decide. The Alliance for Hippocratic Medicine decision is narrow: it holds that these plaintiffs cannot sue under these theories. It does not resolve whether the FDA's actions were arbitrary and capricious under the Administrative Procedure Act. It does not address whether states have standing. It does not constitutionalize access to mifepristone.

Structural accountability requires that legal analysis distinguish between holdings and dicta, between procedural dismissals and merits rulings, and between unanimous judgments and ideological splits. The Court provided a unanimous procedural answer. What happens next depends on whether other plaintiffs can meet the constitutional threshold the Alliance could not—and whether the public understands that the question remains open.